We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

INC Research and Debiopharm Group ™ Announce Strategic Partnership

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

INC Research, LLC, a therapeutically focused contract research organisation (CRO) with a trusted process for delivering reliable results, and Debiopharm Group™, a Swiss-based global biopharmaceutical group with a focus on drug development and companion diagnostics, have announced a strategic partnership.

Under the terms of the agreement, Debiopharm will entrust INC Research with the management of a clinical study linked to an important project in Debiopharm’s pipeline. Both parties have furthermore agreed on a framework partnership pertaining to future clinical studies to be conducted by INC Research for Debiopharm.

“Debiopharm’s reputation and success in establishing partnerships is aligned very closely with our vision of creating strategic relationships that improve the speed, efficiency, and quality of drug development,” said Kelvin Logan, Ph.D., president INC Research Europe and Asia Pacific, who added “we are pleased to offer our therapeutic expertise along with our experience in conducting trials globally to support Debiopharm’s drug development efforts in bringing innovative medicines to market more quickly and efficiently.”

“It is through our successful partnerships that we have been able to build and maintain a truly leading global biopharmaceutical development group, while supporting and conducting several clinical development programmes on a continuous basis” said Dr Rolland-Yves Mauvernay, President and Founder of Debiopharm.

Dr Mauvernay continued, “This partnership with INC Research will significantly help us in our endeavours to conduct our clinical development programmes efficiently, which in turn will enable us to continue to fuel our pipeline with important new medicines.”

INC Research's clinical delivery alliance structures can include complete management of a compound or therapeutic area; management of a specific function or set of critical processes; sharing in the risk and reward of a compound's performance; or acting as the sole source development partner for a customer.

The company's proven experience with process-driven clinical research methods and its popular metrics-based Trusted Process® provides the foundation for successful strategic alliances.